Flexeril is the brand name most people still use for cyclobenzaprine, a muscle relaxant commonly prescribed for short term muscle spasm after an injury or strain. It is not a controlled substance, and it is not one of the drugs that a standard workplace drug test panel is built to detect. That said, cyclobenzaprine has a documented ability to cause a presumptive positive result on a different kind of screen, one that looks for tricyclic antidepressants. Understanding why that happens, and what a lab does about it, matters for both employees taking the medication and the employers and clinics who have to interpret the result.
Cyclobenzaprine is not on the federal five panel
The drug testing panel used across most federally regulated and many private workplace programs traces back to the Mandatory Guidelines for Federal Workplace Drug Testing Programs. That authorized panel covers five drug categories: amphetamines, cocaine, marijuana, opiates, and phencyclidine, with fentanyl added to the authorized panel as of mid 2025. Cyclobenzaprine is not chemically related to any of those five categories, and it is not targeted by the immunoassays built for them. A person taking Flexeril as prescribed will not trigger a positive result on a standard five panel or ten panel workplace screen because of the medication itself.
This is worth stating plainly because search traffic for muscle relaxants and drug tests tends to lump every medication into one bucket, when the real answer depends entirely on which drug classes a given panel is built to detect. A five panel urine cup, a dip card configured for the same five categories, and most oral fluid devices used in general workplace programs are simply not looking for tricyclic antidepressants at all. Nothing about cyclobenzaprine will appear on those results, positive or otherwise, because the antibody reagents on the test strip are not designed to bind to it.
Where the cross reactivity actually comes from
Some clinical toxicology panels and a subset of expanded employment or medical evaluation panels include a separate immunoassay aimed at tricyclic antidepressants, a class that includes drugs such as amitriptyline and imipramine. Cyclobenzaprine was developed from that same chemical family. Pharmacology references note that cyclobenzaprine is structurally related to the tricyclic antidepressants and differs from amitriptyline by only one double bond in its ring structure. Because immunoassay screens work by detecting a molecule's general shape rather than reading its exact identity, a compound this close in structure to amitriptyline can bind to the same antibodies the test uses and produce a positive signal for the tricyclic class, even though no antidepressant was ever taken.
This has been documented in the pharmacy and toxicology literature for years. A widely cited review in the pharmacotherapy literature evaluated cyclobenzaprine's interference with tricyclic antidepressant assays directly and found that immunoassay platforms could not reliably tell the two apart, while chromatographic methods could. Cyclobenzaprine is not the only medication that can cause this kind of tricyclic cross reactivity. Certain antihistamines and other structurally similar compounds are also recognized causes of the same presumptive pattern, which is one reason a single immunoassay screen is never treated as a final answer in a clinical or employment setting.
It helps to remember that an immunoassay is a chemistry shortcut, not an identification test. The reagent is built to recognize a general family shape, which is what makes rapid screening fast and affordable, but it also means any compound sharing enough of that shape can set off the same reaction. That tradeoff is well understood in laboratory medicine and is exactly why every accredited program pairs a screen with a confirmatory method rather than reporting a screen result on its own.
Screening versus confirmation
Every accredited drug testing program is built in two stages, and that distinction is what actually resolves a cyclobenzaprine cross reaction.
| Stage | Method | What it can tell you | Handles a cyclobenzaprine cross reaction? |
|---|---|---|---|
| Initial screen | Immunoassay (point of care cup, dip card, or lab based screen) | Presumptive result only, based on how closely a substance binds to a class specific antibody | No. This is the stage where the cross reaction can appear. |
| Confirmation | Gas chromatography mass spectrometry (GC MS) or liquid chromatography tandem mass spectrometry (LC MS/MS) | Identifies the exact compound present, down to its molecular mass and fragmentation pattern | Yes. Confirmation distinguishes cyclobenzaprine from amitriptyline and other true tricyclic antidepressants and is considered the legally defensible result. |
Published comparisons of the two methods have shown that ultraviolet absorption and mass spectrometry readings for cyclobenzaprine are measurably different from those of amitriptyline, even though the two compounds look similar to an antibody based screen. In practice, this means a presumptive positive on a tricyclic antidepressant immunoassay is never the end of the process. Any accredited laboratory or clinic should send a non negative screen to confirmation before it is reported as a verified result.
How employers and clinics should handle it
For drug testing programs that fall under Department of Transportation rules, a medical review officer reviews every laboratory confirmed non negative result before it reaches the employer. The medical review officer contacts the individual, asks about current prescriptions and other legitimate medical explanations, and verifies the result based on that conversation and any documentation provided. Because tricyclic antidepressants are not part of the federally authorized five panel, this exact regulatory process generally applies to the drugs that are on that panel. Employers running expanded or clinical panels that include a tricyclic antidepressant screen should still route any non negative screen through a qualified medical professional for review before taking any employment action, and should give the employee a chance to provide prescription documentation.
Clinics that build their own expanded panels, and staffing programs that use a third party medical review process, benefit from documenting in writing which drug classes trigger a required medical review and which staff member handles that review. That documentation protects the employee, because it sets a clear path for a legitimate prescription to be considered, and it protects the employer or clinic, because it shows a consistent process was followed rather than an ad hoc decision made by whoever happened to see the result first. State rules on how an employer must handle a positive drug test, including notice and review requirements, vary and should be checked against the jurisdiction where the testing takes place.
Employees who are prescribed cyclobenzaprine do not need to disclose it before testing. If a screen does come back non negative for a tricyclic antidepressant class, the practical step is to make sure confirmation testing is run and to have the prescription information available for whoever is reviewing the result. A valid prescription for a legitimate medical condition is the kind of documentation a reviewing physician or medical review officer would want to see, though outcomes and employer policy on medication disclosure vary and this is not something a testing company can promise in advance.
What this means if you supply or run drug testing
For clinics, staffing agencies, and employers building or buying a testing panel, the practical takeaway is that a tricyclic antidepressant screen adds a known source of presumptive false positives from a common, non controlled muscle relaxant. Programs that do not need to screen for antidepressant misuse can often avoid the issue entirely by sticking to the standard federal five panel or a closely related panel that does not include a TCA immunoassay. Programs that do include a TCA screen, often for clinical or pain management monitoring reasons rather than general employment screening, should build the expectation of occasional cyclobenzaprine cross reactivity into their review process from the start, rather than treating every non negative result as a confirmed finding.
Frequently asked questions
Does Flexeril show up on a standard five panel or ten panel workplace drug test?
No. The federally authorized workplace testing panel covers amphetamines, cocaine, marijuana, opiates, phencyclidine, and, as of 2025, fentanyl. Cyclobenzaprine is not chemically related to any of those categories and will not trigger a positive on that panel.
Can cyclobenzaprine cause a false positive for antidepressants?
It can, but only on a screen that specifically tests for tricyclic antidepressants, which is not part of standard workplace panels. Cyclobenzaprine's molecular structure is close enough to amitriptyline that some immunoassays cannot reliably tell them apart at the screening stage.
How does a lab tell the difference between Flexeril and an actual tricyclic antidepressant?
Through confirmation testing. Gas chromatography mass spectrometry or liquid chromatography tandem mass spectrometry identifies the exact compound based on its mass and fragmentation pattern, which reliably separates cyclobenzaprine from amitriptyline and other tricyclic antidepressants.
Do I need to tell my employer I take Flexeril before a drug test?
Generally you are not required to disclose a prescription medication before testing. If a non negative result comes back on a screen that includes a tricyclic antidepressant panel, having your prescription information available for the reviewing medical professional is the practical next step.
Does this affect DOT regulated or safety sensitive drug testing?
Generally no, because the federally authorized panel used for DOT regulated testing does not include a tricyclic antidepressant screen. This cross reactivity issue mainly comes up on expanded or clinical panels that specifically test for that drug class.
Is a presumptive positive the same as a confirmed positive?
No. An immunoassay screen is a preliminary, presumptive result. Any non negative screening result should go through confirmation testing before it is treated as a verified finding, and DOT regulated results also go through medical review officer verification.
Related reading
- Do muscle relaxers show up on a drug test? Carisoprodol and Soma explained
- The medical review officer (MRO) process explained for employers
Browse verified, CLIA waived drug test cups for workplace and clinic screening programs.
Sources
- Federal Register, Mandatory Guidelines for Federal Workplace Drug Testing Programs, Authorized Testing Panels
- SAMHSA, Workplace Drug Testing Resources
- eCFR, 49 CFR Part 40 Subpart G, Medical Review Officers and the Verification Process
- DailyMed, Cyclobenzaprine Hydrochloride prescribing information
- NCBI Bookshelf, LiverTox, Cyclobenzaprine
- PubMed, Effect of cyclobenzaprine on tricyclic antidepressant assays
This article is general information for employers, clinics, and testing programs. It is not medical or legal advice, and it does not replace guidance from a medical review officer, treating physician, or qualified counsel.
